Literature DB >> 6315321

Oxidative response of phagocytes to parasite invasion.

S J Klebanoff, R M Locksley, E C Jong, H Rosen.   

Abstract

Phagocytes destroy intracellular pathogens and extracellular targets in part by the production of toxic oxygen metabolites--namely, superoxide, hydrogen peroxide, hydroxyl radicals and possibly singlet molecular oxygen. The toxicity of hydrogen peroxide is increased greatly by peroxidase and a halide. A peroxidase that can be used for this purpose is present in neutrophils and monocytes (myeloperoxidase), but is lost when the monocyte matures into a macrophage; a different peroxidase is present in eosinophils. The latter enzyme, because of its strong positive charge, binds to the surface of parasites; any phagocyte in the region, when appropriately stimulated, may provide the hydrogen peroxide required for completion of the peroxidase system. Further, peroxidase-coated organisms are more readily killed when ingested by macrophages than are uncoated organisms. Oxygen-dependent toxicity requires the production of toxic oxygen products by phagocytes in amounts sufficient to overcome the protective capacity of endogenous scavengers in the parasite. The latter include catalase and glutathione peroxidase, which degrade hydrogen peroxide, and superoxide dismutase which dissipates superoxide. The host defence against parasites appears to depend in part on this balance between toxic oxygen metabolites and scavengers.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6315321     DOI: 10.1002/9780470720806.ch6

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  12 in total

Review 1.  Eosinophil-dependent bromination in the pathogenesis of asthma.

Authors:  J W Heinecke
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Protein Radical Formation Resulting from Eosinophil Peroxidase-catalyzed Oxidation of Sulfite.

Authors:  Kalina Ranguelova; Saurabh Chatterjee; Marilyn Ehrenshaft; Dario C Ramirez; Fiona A Summers; Maria B Kadiiska; Ronald P Mason
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

Review 3.  Eosinophils: a review.

Authors:  B J McEwen
Journal:  Vet Res Commun       Date:  1992       Impact factor: 2.459

4.  Parasitophorous vacuoles of Leishmania amazonensis-infected macrophages maintain an acidic pH.

Authors:  J C Antoine; E Prina; C Jouanne; P Bongrand
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

5.  Photoactivation of ROS Production In Situ Transiently Activates Cell Proliferation in Mouse Skin and in the Hair Follicle Stem Cell Niche Promoting Hair Growth and Wound Healing.

Authors:  Elisa Carrasco; María I Calvo; Alfonso Blázquez-Castro; Daniela Vecchio; Alicia Zamarrón; Irma Joyce Dias de Almeida; Juan C Stockert; Michael R Hamblin; Ángeles Juarranz; Jesús Espada
Journal:  J Invest Dermatol       Date:  2015-07-02       Impact factor: 8.551

6.  Eosinophils generate brominating oxidants in allergen-induced asthma.

Authors:  W Wu; M K Samoszuk; S A Comhair; M J Thomassen; C F Farver; R A Dweik; M S Kavuru; S C Erzurum; S L Hazen
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

7.  Micromolar intracellular hydrogen peroxide disrupts metabolism by damaging iron-sulfur enzymes.

Authors:  Soojin Jang; James A Imlay
Journal:  J Biol Chem       Date:  2006-11-13       Impact factor: 5.157

8.  Immunolocalization of superoxide dismutase in Dirofilaria immitis adult worms.

Authors:  H L Callahan; D Hazen-Martin; R K Crouch; E R James
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

9.  Study on myeloperoxidase role in antituberculous defense in the context of cytokine activation.

Authors:  M Koziol-Montewka; A Kolodziejek; J Oles
Journal:  Inflammation       Date:  2004-04       Impact factor: 4.092

10.  Analysis of the mechanism by which melatonin inhibits human eosinophil peroxidase.

Authors:  T Lu; S Galijasevic; I Abdulhamid; H M Abu-Soud
Journal:  Br J Pharmacol       Date:  2008-06-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.